Tucker, GA, United States
Tucker, GA, United States
SEARCH FILTERS
Time filter
Source Type

Pradere U.,Emory University | Garnier-Amblard E.C.,RFS Pharma | Coats S.J.,RFS Pharma | Amblard F.,Emory University | Schinazi R.F.,Emory University
Chemical Reviews | Year: 2014

The article reviews the most important mono-, di-, and triphosphate and phosphonate prodrug approaches applied to nucleoside analogs from a chemical point of view, detailing the strengths and limitations of each approach. The article focuses on the various synthetic pathways discussing the chemical variation of the biolabile phosph(on)ate masking groups, the reliability of using P(III) and/or P(V) chemistry for phosphate and phosphonate prodrug synthesis, and the influence of the masking group(s) introduction conditions on the overall outcome for each method.


Patent
Emory University and RFS Pharma | Date: 2013-09-20

The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.


A method and composition for treating a host infected with a Caliciviridae virus, such as a Norovirus, comprising administering an effective treatment amount of a described modified nucleoside or a pharmaceutically acceptable salt thereof, is provided.


Patent
RFS Pharma and Emory University | Date: 2016-01-06

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.


Patent
Emory University and RFS Pharma | Date: 2012-05-16

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.


Patent
Genoscience and RFS Pharma | Date: 2011-10-28

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.


Patent
RFS Pharma | Date: 2013-01-11

The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.


Patent
RFS Pharma and Emory University | Date: 2014-08-08

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.


Patent
Emory University and RFS Pharma | Date: 2011-08-26

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.


The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, or HBV in human patients or other animal hosts. The compounds are certain N^(4)-hydroxycytidine nucleosides derivatives, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, and HBV.

Loading RFS Pharma collaborators
Loading RFS Pharma collaborators